Diabetes: Is rhabdomyolysis associated with DPP-IV inhibitors?

Last Updated on

October 15, 2017 – According to the quarterly safety report April – June 2017 by the American Food & Drug Administration (FDA), originating from the  FDA Adverse Event Reporting System (FAERS), the class of diabetes drugs referred to as dipeptidyl peptidase-4 inhibitors (DPP-IV inhibitors) may be associated with rhabdomyolysis, a severe,

Rhabdomyolysis

sometimes fatal, adverse drug reaction, which involves severe muscle damage and may lead to renal and kidney failures. In more detail, rhabdomyolysis is the breakdown of muscle tissue that leads to the release of muscle fiber contents into the blood. These substances are harmful to the kidney and often cause kidney damage.

This most recent FDA quarterly report was issued in early October 2017.  It states that “FDA is evaluating the need for regulatory action” as regards this possible rhabdomyolysis side effect for these oral diabetes drugs: Empagliflozin/Linagliptin (Glyxambi), Sitagliptin/Metformin (Janumet), Sitagliptin/Metformin (Janumet XR), Sitagliptin (Januvia), Linagliptin/Metformin(Jentadueto), Linagliptin/Metformin (Jentadueto XR), Alogliptin/Metformin (Kazano). Saxagliptin/Metformin (Kombiglyze XR), Alogliptin (Nesina), Saxagliptin (Onglyza), Alogliptin/Pioglitazone (Oseni), Dapagliflozin/Saxagliptin (Qtern), Linagliptin (Tradjenta).

In may be of particular interest to note that previously the FDA had announced that it was evaluating the need for regulatory action for the DPP-IV inhibitor class of diabetes medicines due to the serious side effect of renal and/or kidney failure, as announced in the quarterly report from  July – September 2015. It would not be too surprising if most of these cases of renal and/or kidney failure had rhabdomyolysis as an underlying etiologic clinical factor.

DPP-IV inhibitors are often also referred to as gliptines. Besides the afore listed gliptines on the market in the United States, gliptines are on the market in other parts of the world as follows: Vildagliptin (Galvus) in the European Union ((EU), Gemigliptin (Zemiglo) in South Korea, Anagliptin, Teneligliptin, and Omarigliptin in Japan, and Evogliptin (approved for use in South Korea). Worldwide, this list may not be complete; however, it is fair to assume that all patients taking gliptine-type of drugs (i.e., DPP-IV inhibitors) may have a risk of being afflicted with rhabdomyolysis and ensuing renal and or kidney failures.

If there exist a genetic predisposition for the development of rhabdomyolysis after drug exposure is still at the research level. There seem to exist genetic factors that predispose patients for the development of rhabdomyolysis (even some inherited forms seem to exist); how drug exposure, in particular to DPP-IV inhibitors may influence the risk for development of rhabdomyolysis in carriers of such predisposing factors remains at present an open question.

Here, you may find all the FDA’s Quarterly Safety Reports since 2009 0n “Potential Signals of Serious Risks/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS)”.

 

____________________

 

Tags: , , , , , , , , , , , , , , , , , , , , , , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Leave a Reply

Optional: Social Subscribe/Login




avatar
  Subscribe  
Notify of

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Genes, the social environment, and adolescent smoking September 17, 2019
    Adolescence is a time of dramatic change. It marks a period of significant physical transformation—such as the drive toward sexual maturity. But it can also be a time of considerable psychological change and social experimentation.
  • Cause of rare, fatal disorder in young children pinpointed September 17, 2019
    Scientists at Washington University School of Medicine in St. Louis appear to have solved a decades-long mystery regarding the precise biochemical pathway leading to a fatal genetic disorder in children that results in seizures, developmental regression and death, usually around age 3. Studying a mouse model with the same human illness—called Krabbe disease—the researchers also […]
  • Gene-targeted cancer drugs, slow release overcome resistance September 16, 2019
    Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, protein engineering and biomaterials science to improve the efficacy, accuracy and longevity of certain cancer therapies.
  • Genetic mutation appears to protect some people from deadly MRSA September 16, 2019
    An inherited genetic tendency appears to increase the likelihood that a person can successfully fight off antibiotic-resistant staph infections, according to a study led by Duke Health researchers.
  • Renegade genes caught red handed September 16, 2019
    The guardians of the human genome that work to prevent potentially disease-causing gene expression might not be as effective at their jobs as previously thought, according to new University of Arizona research.
Top